CN114716569B - Recombinant protein, recombinant expression vector, recombinant bacteria and application of recombinant protein carrying target protein to autonomously enter eukaryotic cells - Google Patents
Recombinant protein, recombinant expression vector, recombinant bacteria and application of recombinant protein carrying target protein to autonomously enter eukaryotic cells Download PDFInfo
- Publication number
- CN114716569B CN114716569B CN202210384441.0A CN202210384441A CN114716569B CN 114716569 B CN114716569 B CN 114716569B CN 202210384441 A CN202210384441 A CN 202210384441A CN 114716569 B CN114716569 B CN 114716569B
- Authority
- CN
- China
- Prior art keywords
- recombinant
- protein
- svnls
- cells
- mrphr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 95
- 239000013604 expression vector Substances 0.000 title claims abstract description 25
- 238000003259 recombinant expression Methods 0.000 title claims abstract description 21
- 241000894006 Bacteria Species 0.000 title claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 title abstract description 89
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract description 45
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract description 45
- 210000003527 eukaryotic cell Anatomy 0.000 title abstract description 10
- 230000005855 radiation Effects 0.000 claims abstract description 36
- 230000008439 repair process Effects 0.000 claims abstract description 22
- 230000005778 DNA damage Effects 0.000 claims abstract description 18
- 231100000277 DNA damage Toxicity 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 241000255601 Drosophila melanogaster Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 241000223201 Metarhizium Species 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 88
- 108010046331 Deoxyribodipyrimidine photo-lyase Proteins 0.000 abstract description 29
- 108091093078 Pyrimidine dimer Proteins 0.000 abstract description 27
- 108020004414 DNA Proteins 0.000 abstract description 24
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 23
- 229940118019 malondialdehyde Drugs 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004940 nucleus Anatomy 0.000 abstract description 18
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 17
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 17
- 230000003834 intracellular effect Effects 0.000 abstract description 17
- 101001125632 Agrobacterium fabrum (strain C58 / ATCC 33970) Deoxyribodipyrimidine photo-lyase Proteins 0.000 abstract description 13
- 210000003855 cell nucleus Anatomy 0.000 abstract description 8
- 210000005260 human cell Anatomy 0.000 abstract description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 abstract description 7
- 239000001301 oxygen Substances 0.000 abstract description 7
- 102000037865 fusion proteins Human genes 0.000 abstract description 6
- 108020001507 fusion proteins Proteins 0.000 abstract description 6
- 210000000170 cell membrane Anatomy 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 59
- 239000005090 green fluorescent protein Substances 0.000 description 38
- 238000000034 method Methods 0.000 description 17
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 16
- 239000003642 reactive oxygen metabolite Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 239000000287 crude extract Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 229910052759 nickel Inorganic materials 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 235000019750 Crude protein Nutrition 0.000 description 6
- 241000672609 Escherichia coli BL21 Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 101000684503 Homo sapiens Sentrin-specific protease 3 Proteins 0.000 description 5
- 241000223250 Metarhizium anisopliae Species 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091093105 Nuclear DNA Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000000254 composite pulse decoupling sequence Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000014304 histidine Nutrition 0.000 description 4
- 150000002411 histidines Chemical class 0.000 description 4
- 230000001678 irradiating effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000020520 nucleotide-excision repair Effects 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010018628 Ulp1 protease Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- GMRGSBAMMMVDGG-GUBZILKMSA-N Asn-Arg-Arg Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N GMRGSBAMMMVDGG-GUBZILKMSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 230000010596 Gene Editing or Modification Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- FFAUOCITXBMRBT-YTFOTSKYSA-N Ile-Lys-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FFAUOCITXBMRBT-YTFOTSKYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- DJJBHQHOZLUBCN-WDSOQIARSA-N Met-Lys-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DJJBHQHOZLUBCN-WDSOQIARSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000009011 OxiSelect In Vitro ROS/RNS Assay Kit Methods 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102100023645 Sentrin-specific protease 3 Human genes 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- ZHDQRPWESGUDST-JBACZVJFSA-N Trp-Phe-Gln Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CC=CC=C1 ZHDQRPWESGUDST-JBACZVJFSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010043322 lysyl-tryptophyl-alpha-lysine Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 108700029760 synthetic LTSP Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/99—Other Carbon-Carbon Lyases (1.4.99)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供了一种携带目标蛋白自主进入真核细胞的重组蛋白、重组表达载体和重组菌及应用,涉及融合蛋白技术领域。本发明所述重组蛋白,从N端至C端,依次包括将所述重组蛋白带入细胞核中的入核信号NLS‑目标蛋白‑具跨越细胞膜能力的短肽AE1。其中AE1无毒高效地带领重组蛋白跨越细胞膜进入细胞内,并由NLS将目标蛋白带入到细胞核中,从而发生作用。本发明还提供了一种能自主进入人类细胞核修复UV辐射诱发的DNA损伤的重组光解酶,以CPD光解酶为目标蛋白,具有修复细胞核DNA上的环丁烷嘧啶二聚体(CPD)、提高胞内超氧化物歧化酶(SOD)活性,以及降低胞内氧自由基(ROS)和剧毒分子丙二醛(MDA)水平的作用。
The invention provides a recombinant protein, a recombinant expression vector, a recombinant bacterium and an application that can carry a target protein into eukaryotic cells autonomously, and relates to the technical field of fusion proteins. The recombinant protein of the present invention, from the N-terminus to the C-terminus, sequentially includes the nuclear entry signal NLS-target protein-the short peptide AE1 with the ability to cross the cell membrane, which brings the recombinant protein into the cell nucleus. Among them, AE1 non-toxically and efficiently leads the recombinant protein across the cell membrane into the cell, and NLS brings the target protein into the nucleus, where it takes effect. The present invention also provides a recombinant photolyase that can autonomously enter the human cell nucleus to repair DNA damage induced by UV radiation. It uses CPD photolyase as the target protein and has the ability to repair cyclobutane pyrimidine dimer (CPD) on the DNA of the cell nucleus. , increase intracellular superoxide dismutase (SOD) activity, and reduce intracellular oxygen free radicals (ROS) and highly toxic molecule malondialdehyde (MDA) levels.
Description
技术领域Technical field
本发明属于融合蛋白技术领域,具体涉及一种携带目标蛋白自主进入真核细胞的重组蛋白、重组表达载体和重组菌及应用。The invention belongs to the technical field of fusion proteins, and specifically relates to a recombinant protein that carries a target protein and enters eukaryotic cells autonomously, a recombinant expression vector, a recombinant bacterium, and their applications.
背景技术Background technique
紫外线辐射会对人类产生许多的危害。太阳光中的紫外线按照波长分为3类,其一是短波紫外线(UVC:200~280nm),它几乎都被大气臭氧层吸收。其二是中波紫外线(UVB:290~320nm),它在太阳光中紫外线的占比大概只有5%,包括急性晒伤和色素沉着在内的表皮损伤主要是由UVB引起的。其三是长波紫外线(UVA:320~400nm),它在太阳光中紫外线的占比高达95%。长波紫外线穿透能力强,可达到皮肤深层,容易导致皮肤黑化和光老化。有研究表明,皮肤癌是过度暴露于紫外线辐射下的主要病理表现,地表紫外辐射中的UVA、UVB与大多数的皮肤癌相关,包括鳞状细胞癌(SCCs)、皮肤恶性黑色素瘤(CMMs)等,其中非黑色素瘤皮肤癌(NMSCs)占所有皮肤癌的90%以上[1,2]。Ultraviolet radiation can cause many harms to humans. Ultraviolet rays in sunlight are divided into three categories according to wavelength. One is short-wave ultraviolet rays (UVC: 200~280nm), which are almost all absorbed by the atmospheric ozone layer. The second is mid-wave ultraviolet rays (UVB: 290-320nm), which account for only about 5% of ultraviolet rays in sunlight. Epidermal damage, including acute sunburn and pigmentation, is mainly caused by UVB. The third is long-wave ultraviolet rays (UVA: 320~400nm), which accounts for up to 95% of ultraviolet rays in sunlight. Long-wave ultraviolet rays have strong penetrating ability and can reach deep layers of the skin, easily causing skin blackening and photoaging. Studies have shown that skin cancer is the main pathological manifestation of overexposure to ultraviolet radiation. UVA and UVB in surface ultraviolet radiation are related to most skin cancers, including squamous cell carcinomas (SCCs) and cutaneous malignant melanomas (CMMs). etc., among which non-melanoma skin cancers (NMSCs) account for more than 90% of all skin cancers [1,2] .
紫外线辐射产生的细胞核DNA光产物(photoproduct)是诱发基因突变和皮肤癌发生的主要原因。UVB辐射是太阳光中最具能量和诱变很强的成分,它直接被DNA吸收,并在相邻的两个嘧啶碱基之间诱导形成二聚体光产物[3]。紫外辐射主要诱发产生两种类型的DNA二聚体光产物:环丁烷嘧啶二聚体(cyclobutane pyrimidine dimer,CPD)和(6-4)嘧啶酮光产物(6-4photoproduct,6-4PPs)。这两种光损伤都会扭曲DNA螺旋,并干扰细胞转录和复制过程,从而引发DNA突变、RNA合成抑制、细胞周期停滞和细胞凋亡等[4]。紫外线诱导产生的DNA损伤中大约70~80%是CPDs,其余是6-4PPs和6-4PPs的杜瓦异构体。尽管6-4PPs在大肠杆菌中有明显的致突变性,但哺乳动物细胞修复6-4PPs的速度比CPDs快得多。因此,在哺乳动物细胞中,相对于6-4PPs来说,紫外线诱导产生的CPDs所导致的突变明显更多[5]。除了6-4PPs和CPDs,紫外线也可能通过产生单线态氧或自由基间接造成DNA损伤,例如通过激活核黄素、色氨酸和卟啉等可以活化细胞氧的小分子产生活性氧(ROS)。ROS可以通过诱导受照射细胞产生氧化性碱基损伤或直接攻击DNA分子的糖磷酸主干,促进DNA单链断裂[8]。另外,氧自由基可以作用于脂质的不饱和脂肪酸,生成过氧化脂质,后者逐渐分解为一系列复杂的化合物,其中包括丙二醛(MDA),通过检测MDA的水平即可检测脂质氧化的水平,间接地反映出细胞损伤的程度。此外,MDA还是一种剧毒分子,它能够通过与DNA和蛋白质等分子发生反应从而损害人体多种生理机制,如MDA与核酸碱基相互作用形成的加合物中有的具有致突变性、MDA与胶原蛋白交联可能会显著促进心血管组织的硬化[9]。The nuclear DNA photoproducts (photoproducts) produced by ultraviolet radiation are the main cause of inducing gene mutations and skin cancer. UVB radiation is the most energetic and highly mutagenic component of sunlight. It is directly absorbed by DNA and induces the formation of dimer photoproducts between two adjacent pyrimidine bases [3] . Ultraviolet radiation mainly induces the production of two types of DNA dimer photoproducts: cyclobutane pyrimidine dimer (CPD) and (6-4) pyrimidinone photoproduct (6-4photoproduct, 6-4PPs). Both types of light damage can distort DNA helices and interfere with cellular transcription and replication processes, thereby causing DNA mutations, inhibition of RNA synthesis, cell cycle arrest, and apoptosis [4] . About 70 to 80% of the DNA damage induced by ultraviolet rays is CPDs, and the rest is 6-4PPs and Dewar isomers of 6-4PPs. Although 6-4PPs are significantly mutagenic in E. coli , mammalian cells repair 6-4PPs much faster than CPDs. Therefore, in mammalian cells, UV-induced CPDs cause significantly more mutations than 6-4PPs [5] . In addition to 6-4PPs and CPDs, UV rays may also cause DNA damage indirectly by producing singlet oxygen or free radicals, for example, by activating small molecules such as riboflavin, tryptophan, and porphyrins that can activate cellular oxygen to produce reactive oxygen species (ROS). . ROS can promote DNA single-strand breaks by inducing oxidative base damage in irradiated cells or directly attacking the sugar-phosphate backbone of DNA molecules [8] . In addition, oxygen free radicals can act on the unsaturated fatty acids of lipids to generate peroxidized lipids, which gradually decompose into a series of complex compounds, including malondialdehyde (MDA). Lipids can be detected by detecting the level of MDA. The level of plasma oxidation indirectly reflects the degree of cell damage. In addition, MDA is also a highly toxic molecule that can damage various physiological mechanisms of the human body by reacting with molecules such as DNA and proteins. For example, some of the adducts formed by the interaction between MDA and nucleic acid bases are mutagenic, Cross-linking of MDA and collagen may significantly promote the hardening of cardiovascular tissue [9] .
光解酶(photolyase)也称光裂合酶,是一种黄素蛋白,它可以通过吸收蓝光修复紫外线辐射所诱发的DNA光产物[6]。自然界存在两种不同类型的光解酶,分别是修复CPD的CPD光解酶和修复6-4PPs的6-4PP光解酶。尽管这两类光解酶在结构上类似,但它们具有很强的底物特异性[2]。然而,人类细胞先天并不存在光解酶,针对于紫外辐射造成的DNA光产物,人类只能通过其它的涉及多种蛋白的复杂机制进行修复,如核苷酸切除修复(NER)途径。相对于其它物种中的光解酶直接修复途径,人类细胞通过NER修复CPD的效率低下,并且基于NER的CPD修复效率还会随着年龄的增长进一步降低,导致DNA损伤逐渐积累,引发一系列的多种病变,甚至癌症[7]。Photolyase, also known as photolyase, is a flavoprotein that can repair DNA photoproducts induced by ultraviolet radiation by absorbing blue light [6] . There are two different types of photolyase in nature, namely CPD photolyase that repairs CPD and 6-4PP photolyase that repairs 6-4PPs. Although these two types of photolyases are similar in structure, they have strong substrate specificity [2] . However, human cells are not born with photolytic enzymes. For DNA photoproducts caused by ultraviolet radiation, humans can only repair them through other complex mechanisms involving multiple proteins, such as the nucleotide excision repair (NER) pathway. Compared with the direct repair pathway of photolytic enzymes in other species, the efficiency of human cells in repairing CPD through NER is low, and the efficiency of NER-based CPD repair will further decrease with age, leading to the gradual accumulation of DNA damage and triggering a series of A variety of lesions, even cancer [7] .
当前,人们采用多种物理方式来防紫外辐射,包括使用遮阳伞和防晒衣等防护用具,涂抹具有适当防晒系数(SPF)和防护光谱的防晒霜,以及通过在洗衣粉中添加紫外吸收剂来提高衣服的紫外线防护系数等。除此之外,有研究表明,在防晒霜中添加含包括上述光解酶在内的DNA修复酶的脂质体,后者可将修复酶转入细胞中以修复紫外线诱发的DNA损伤[2]。尽管基于脂质体技术的化妆品已有广泛应用,但是它存在制备技术要求高、脂质体稳定性差,与化妆品中其他原料配伍不易等问题,容易出现沉淀、磷脂容易氧化变色、易产生特异性气味等不良现象。Currently, people use a variety of physical methods to protect against UV radiation, including using protective equipment such as parasols and sun-protective clothing, applying sunscreen with appropriate sun protection factor (SPF) and protective spectrum, and adding UV absorbers to laundry detergent. Improve the UV protection factor of clothing, etc. In addition, studies have shown that adding liposomes containing DNA repair enzymes including the above-mentioned photolytic enzymes to sunscreen can transfer the repair enzymes into cells to repair UV-induced DNA damage [2 ] . Although cosmetics based on liposome technology have been widely used, they have problems such as high preparation technology requirements, poor stability of liposomes, and difficulty in compatibility with other raw materials in cosmetics. They are prone to precipitation, phospholipids are prone to oxidation and discoloration, and are prone to specificity. Undesirable phenomena such as odor.
参考文献references
[1]Jean Cadet,Thierry Douki,Jean-Luc Ravanat.Oxidatively GeneratedDamage to Cellular DNA by UVB and UVA Radiation[J].Photochemistry andPhotobiology,2015,91:140-155.[1]Jean Cadet,Thierry Douki,Jean-Luc Ravanat.Oxidatively GeneratedDamage to Cellular DNA by UVB and UVA Radiation[J].Photochemistry andPhotobiology,2015,91:140-155.
[2]Marie-Therese Leccia,Celeste Lebbe,Jean-Paul,et al.New Vision inPhotoprotection and Photorepair[J].Dermatol Ther(Heidelb),2019,9:103-115.[2]Marie-Therese Leccia,Celeste Lebbe,Jean-Paul,et al.New Vision inPhotoprotection and Photorepair[J].Dermatol Ther(Heidelb),2019,9:103-115.
[3]Cadet J,Sage E,Douki T.Ultraviolet radiation-mediated damage tocellular DNA.MutatRes.2005,571:3-17.[3] Cadet J, Sage E, Douki T. Ultraviolet radiation-mediated damage to cellular DNA. MutatRes.2005,571:3-17.
[4]George A Garinis,Judith Jans,et al.Photolyases:capturing the lightto battle skin cancer[J].Future Oncol,2006,2(2):191-199.[4]George A Garinis,Judith Jans,et al.Photolyases:capturing the light to battle skin cancer[J].Future Oncol,2006,2(2):191-199.
[5]Silvia Tornaletti,Gerd P.Pfeifer.UV damage and repair mechanismsin mammalian cells[J].BioEssays,1996,18(3):221-228.[5]Silvia Tornaletti,Gerd P.Pfeifer.UV damage and repair mechanisms in mammalian cells[J].BioEssays,1996,18(3):221-228.
[6]Navarrete-Dechent C,Molgo M.The use of a sunscreen containing DNA-photolyase in the treatment ofpatients with field cancerization and multipleactinic keratoses:a case-series[J].Dermatol Online.2017:15-23.[6]Navarrete-Dechent C, Molgo M. The use of a sunscreen containing DNA-photolyase in the treatment of patients with field cancerization and multipleactinic keratoses: a case-series[J].Dermatol Online.2017:15-23.
[7]de Laat WL,Jaspers NGJ,Hoeijmakers JHJ.Molecular mechanism ofnucleotide excision repair.Genes Dev.1999,13(7):768-85.[7] de Laat WL, Jaspers NGJ, Hoeijmakers JHJ. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999, 13(7): 768-85.
[8]Brem,R.,M.Guven,P.Karran.Oxidatively-generated damage to DNA andproteins mediated by photosensitized UVA.Free Radical Biology andMedicine.2017,107:101-109.[8] Brem, R., M. Guven, P. Karran. Oxidatively-generated damage to DNA and proteins mediated by photosensitized UVA. Free Radical Biology and Medicine. 2017, 107: 101-109.
[9]Daniele Del Rio,Amanda J.Stewart,Nicoletta Pellegrini.A review ofrecent studies on malondialdehyde as toxic molecule and biological marker ofoxidative stress.Nutrition,Metabolism&Cardiovascular Diseases.2005,15:316-328.[9] Daniele Del Rio, Amanda J. Stewart, Nicoletta Pellegrini. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutrition, Metabolism & Cardiovascular Diseases. 2005, 15: 316-328.
发明内容Contents of the invention
有鉴于此,本发明的目的在于提供一种携带目标蛋白自主进入真核细胞的重组蛋白、重组表达载体和重组菌及应用,所述重组蛋白能自行进入真核生物的细胞核,直接使功能目标蛋白质在细胞中发挥作用。当目标蛋白为重组光解酶时,进入细胞核的重组光解酶可用于修复紫外线辐射诱导基因组DNA产生的环丁烷嘧啶二聚体,修复DNA损伤,同时提高胞内超氧化物歧化酶(SOD)活性,以及降低胞内氧自由基(ROS)和剧毒分子丙二醛(MDA)水平的作用,进而有望降低癌变的几率。In view of this, the purpose of the present invention is to provide a recombinant protein, a recombinant expression vector and a recombinant bacterium that carry a target protein and enter eukaryotic cells autonomously and their applications. The recombinant protein can enter the nucleus of eukaryotes by itself and directly make the functional target Proteins perform functions in cells. When the target protein is a recombinant photolyase, the recombinant photolyase that enters the cell nucleus can be used to repair the cyclobutane pyrimidine dimers produced in genomic DNA induced by ultraviolet radiation, repair DNA damage, and at the same time increase intracellular superoxide dismutase (SOD) ) activity, as well as the effect of reducing the levels of intracellular oxygen free radicals (ROS) and the highly toxic molecule malondialdehyde (MDA), which is expected to reduce the chance of cancer.
为了实现上述发明目的,本发明提供以下技术方案:In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
本发明提供了一种携带目标蛋白自主进入真核细胞的重组蛋白,所述重组蛋白的结构,从N端至C端,依次包括入核信号NLS、目标蛋白和短肽AE1。The invention provides a recombinant protein that carries a target protein and enters eukaryotic cells autonomously. The structure of the recombinant protein, from the N-terminus to the C-terminus, includes the nuclear entry signal NLS, the target protein and the short peptide AE1 in sequence.
优选的,所述目标蛋白包括CPD光解酶。Preferably, the target protein includes CPD photolyase.
本发明还提供了一种能自主进入人类细胞核修复UV辐射诱发DNA损伤的重组光解酶,所述重组光解酶的结构,从N端至C端,依次包括:来源于SV40病毒的入核信号、CPD光解酶和来源于黑腹果蝇的短肽AE1。The present invention also provides a recombinant photolyase that can autonomously enter the human cell nucleus to repair DNA damage induced by UV radiation. The structure of the recombinant photolyase, from the N-terminus to the C-terminus, sequentially includes: derived from the SV40 virus. signal, CPD photolyase and the short peptide AE1 from Drosophila melanogaster.
优选的,所述入核信号的氨基酸序列如SEQ ID NO.1所示;Preferably, the amino acid sequence of the nuclear import signal is shown in SEQ ID NO. 1;
所述CPD光解酶包括来源于罗伯茨绿僵菌的CPD光解酶;The CPD photolytic enzyme includes CPD photolytic enzyme derived from Metarhizium anisopliae;
所述短肽AE1的氨基酸序列如SEQ ID NO.2所示。The amino acid sequence of the short peptide AE1 is shown in SEQ ID NO. 2.
优选的,所述DNA损伤包括环丁烷嘧啶二聚体的DNA损伤。Preferably, the DNA damage includes DNA damage of cyclobutane pyrimidine dimers.
本发明还提供了表达上述重组蛋白或上述重组光解酶的重组表达载体,所述重组表达载体包括编码所述重组蛋白或所述重组光解酶的基因。The present invention also provides a recombinant expression vector for expressing the above-mentioned recombinant protein or the above-mentioned recombinant photolyase, and the recombinant expression vector includes a gene encoding the above-mentioned recombinant protein or the above-mentioned recombinant photolyase.
优选的,所述重组表达载体的基础载体包括pET-28a-sumo载体。Preferably, the basic vector of the recombinant expression vector includes pET-28a-sumo vector.
本发明还提供了表达上述重组蛋白或上述重组光解酶的重组菌,所述重组菌的基因组中包括编码所述重组蛋白或所述重组光解酶的基因或上述重组表达载体。The present invention also provides a recombinant bacterium expressing the above recombinant protein or the above recombinant photolyase, and the genome of the recombinant bacterium includes a gene encoding the recombinant protein or the above recombinant photolyase or the above recombinant expression vector.
优选的,所述重组菌的基础菌株包括大肠杆菌。Preferably, the basic strain of the recombinant bacteria includes Escherichia coli.
本发明还提供了上述重组光解酶在制备用于治疗UV辐射诱发的环丁烷嘧啶二聚体的DNA损伤的药物中的应用。The present invention also provides the application of the above-mentioned recombinant photolyase in preparing a drug for treating DNA damage of cyclobutane pyrimidine dimers induced by UV radiation.
有益效果:本发明提供了一种携带目标蛋白自主进入真核细胞的重组蛋白,从N端至C端,依次包括将所述重组蛋白带入细胞核中的入核信号NLS、目标蛋白和具跨越细胞膜能力的短肽AE1。其中AE1无毒高效地带领目标蛋白跨越细胞膜进入细胞内,进一步由NLS将目标蛋白带入到细胞核中,从而发生作用。Beneficial effects: The present invention provides a recombinant protein that carries a target protein and enters eukaryotic cells autonomously. From the N-terminus to the C-terminus, it sequentially includes the nuclear entry signal NLS that brings the recombinant protein into the nucleus, the target protein and the cross-linking protein. Cell membrane-competent short peptide AE1. Among them, AE1 leads the target protein across the cell membrane into the cell in a non-toxic and efficient manner, and further the target protein is brought into the nucleus by NLS, where it takes effect.
本发明还提供了一种能自主进入人类细胞核修复UV辐射诱发DNA损伤的重组光解酶,以CPD光解酶为目标蛋白,具有修复细胞核DNA上的CPD损伤的作用。The present invention also provides a recombinant photolyase that can autonomously enter human cell nuclei to repair DNA damage induced by UV radiation. It uses CPD photolyase as a target protein and has the function of repairing CPD damage on cell nuclear DNA.
附图说明Description of the drawings
图1为pET-28a-sumo-SVNLS-GFP-AE1、pET-28a-sumo-SVNLS-MrPHR1-AE1、pET-28a-sumo-MrPHR1-AE1、pET-28a-sumo-SVNLS-MrPHR1的载体图谱;Figure 1 is the vector map of pET-28a-sumo-SVNLS-GFP-AE1, pET-28a-sumo-SVNLS-MrPHR1-AE1, pET-28a-sumo-MrPHR1-AE1, and pET-28a-sumo-SVNLS-MrPHR1;
图2为SVNLS::GFP::AE1蛋白表达和纯化的SDS-PAGE分析,M:Marker,1:pET-28a-sumo空载菌株总蛋白粗提液,2:SUMO::SVNLS::GFP::AE1总蛋白粗提液,3:粗提液2的上清,4:纯化的SUMO::SVNLS::GFP::AE1蛋白液,5:加入ULP1酶切去除SUMO后的SVNLS::GFP::AE1蛋白液;Figure 2 shows SDS-PAGE analysis of SVNLS::GFP::AE1 protein expression and purification, M: Marker, 1: pET-28a-sumo empty strain total protein crude extract, 2: SUMO::SVNLS::GFP: : AE1 total protein crude extract, 3: supernatant of crude extract 2, 4: purified SUMO::SVNLS::GFP::AE1 protein solution, 5: SVNLS::GFP: after adding ULP1 enzyme to remove SUMO. :AE1 protein liquid;
图3为使用流式细胞仪分析SVNLS-GFP-AE1蛋白与GFP蛋白进入HFF-1细胞情况;Figure 3 shows the use of flow cytometry to analyze the entry of SVNLS-GFP-AE1 protein and GFP protein into HFF-1 cells;
图4为使用荧光显微镜观察SVNLS::GFP::AE1蛋白进HFF-1细胞核情况,比例尺10μm;Figure 4 shows the observation of the entry of SVNLS::GFP::AE1 protein into the nucleus of HFF-1 cells using a fluorescence microscope, the scale bar is 10 μm;
图5为SVNLS::MrPHR1::AE1蛋白表达和纯化的SDS-PAGE分析,M:Marker,1:pET-28a-sumo空载菌株总蛋白粗提液,2:SUMO::SVNLS::MrPHR1::AE1总蛋白粗提液,3:粗提液2的上清,4:纯化的SUMO::SVNLS::MrPHR1::AE1蛋白液,5:加入ULP1酶切去除SUMO后的SVNLS::MrPHR1::AE1蛋白液;Figure 5 shows SDS-PAGE analysis of SVNLS::MrPHR1::AE1 protein expression and purification, M: Marker, 1: pET-28a-sumo empty strain total protein crude extract, 2: SUMO::SVNLS::MrPHR1: : AE1 total protein crude extract, 3: supernatant of crude extract 2, 4: purified SUMO::SVNLS::MrPHR1::AE1 protein solution, 5: SVNLS::MrPHR1: after adding ULP1 enzyme to remove SUMO: :AE1 protein liquid;
图6为MrPHR1::AE1及SVNLS::MrPHR1蛋白表达与纯化的SDS-PAGE分析,M:Marker,1:pET-28a-sumo空载菌株总蛋白粗提液,2:SUMO::SVNLS::MrPHR1总蛋白粗提液,3:粗提液2的上清,4:纯化的SUMO::SVNLS::MrPHR1蛋白液,5:加入ULP1酶切去除SUMO后的SVNLS::MrPHR1蛋白液,6:SUMO::MrPHR1::AE1总蛋白粗提液,7:粗提液6的上清,8:纯化的SUMO::MrPHR1::AE1蛋白液,9:加入ULP1酶切去除SUMO后的MrPHR1::AE1蛋白液;Figure 6 shows SDS-PAGE analysis of MrPHR1::AE1 and SVNLS::MrPHR1 protein expression and purification, M: Marker, 1: pET-28a-sumo empty strain total protein crude extract, 2: SUMO::SVNLS:: MrPHR1 total protein crude extract, 3: supernatant of crude extract 2, 4: purified SUMO::SVNLS::MrPHR1 protein solution, 5: SVNLS::MrPHR1 protein solution after adding ULP1 enzyme to remove SUMO, 6: SUMO::MrPHR1::AE1 total protein crude extract, 7: supernatant of crude extract 6, 8: purified SUMO::MrPHR1::AE1 protein solution, 9: MrPHR1:: after adding ULP1 enzyme to remove SUMO. AE1 protein liquid;
图7为ELISA检测SVNLS::MrPHR1::AE1蛋白修复细胞核DNA的CPD损伤的能力;其中1-8表示不同条件处理的HFF-1细胞提取的基因组DNA,1:未经任何处理的阴性对照;2:UV辐射;3:UV辐射后可见光照射处理;4:与SVNLS::GFP::AE1蛋白共孵育的细胞经UV辐射后可见光照射处理;5:与SVNLS::MrPHR1蛋白共孵育的细胞经UV辐射后可见光照射处理;6:与MrPHR1::AE1蛋白共孵育的细胞经UV辐射后可见光照射处理;7:与SVNLS::MrPHR1::AE1蛋白共孵育的细胞经UV辐射处理;8:与SVNLS::MrPHR1::AE1蛋白共孵育的细胞经UV辐射后可见光照射处理;Figure 7 is an ELISA test for the ability of SVNLS::MrPHR1::AE1 protein to repair CPD damage to nuclear DNA; 1-8 represent genomic DNA extracted from HFF-1 cells treated with different conditions, 1: negative control without any treatment; 2: UV irradiation; 3: UV irradiation followed by visible light irradiation; 4: Cells incubated with SVNLS::GFP::AE1 protein were treated with UV irradiation followed by visible light irradiation; 5: Cells incubated with SVNLS::MrPHR1 protein were UV radiation followed by visible light irradiation treatment; 6: Cells incubated with MrPHR1::AE1 protein were treated with UV radiation followed by visible light irradiation; 7: Cells incubated with SVNLS::MrPHR1::AE1 protein were treated with UV radiation; 8: With Cells co-incubated with SVNLS::MrPHR1::AE1 proteins were treated with UV radiation and then visible light irradiation;
图8为SVNLS::MrPHR1::AE1蛋白降低细胞内由UV辐射诱导产生的氧自由基(ROS)的水平,其中1-6表示不同条件处理的HFF-1细胞,1:未经任何处理的阴性对照;2:UV辐射;3:UV辐射后可见光照射处理;4:与SVNLS::MrPHR1蛋白共孵育的细胞经UV辐射后可见光照射处理;5:与MrPHR1::AE1蛋白共孵育的细胞经UV辐射后可见光照射处理;6:与SVNLS::MrPHR1::AE1蛋白共孵育的细胞经UV辐射后可见光照射处理;Figure 8 shows that SVNLS::MrPHR1::AE1 protein reduces the level of oxygen free radicals (ROS) induced by UV radiation in cells, where 1-6 represents HFF-1 cells treated with different conditions, 1: without any treatment Negative control; 2: UV radiation; 3: UV radiation followed by visible light irradiation treatment; 4: Cells incubated with SVNLS::MrPHR1 protein were treated with UV radiation followed by visible light irradiation; 5: Cells co-incubated with MrPHR1::AE1 protein were treated with UV radiation followed by visible light irradiation treatment; 6: Cells incubated with SVNLS::MrPHR1::AE1 protein were UV irradiated followed by visible light irradiation treatment;
图9为SVNLS::MrPHR1::AE1蛋白降低细胞内UV辐射诱导产生的丙二醛(MDA)的水平,其中1-6表示不同条件处理的HFF-1细胞,同图8;Figure 9 shows that SVNLS::MrPHR1::AE1 protein reduces the level of malondialdehyde (MDA) induced by UV radiation in cells, where 1-6 represent HFF-1 cells treated with different conditions, the same as Figure 8;
图10为SVNLS::MrPHR1::AE1蛋白进一步提高UV辐射细胞内超氧化物歧化酶(SOD)的活性,其中1-6表示不同条件处理的HFF-1细胞,同图8。Figure 10 shows that the SVNLS::MrPHR1::AE1 protein further increases the activity of superoxide dismutase (SOD) in cells exposed to UV radiation, where 1-6 represent HFF-1 cells treated with different conditions, the same as Figure 8.
具体实施方式Detailed ways
本发明提供了一种携带目标蛋白自主进入真核细胞的重组蛋白,所述重组蛋白的结构,从N端至C端,依次包括入核信号NLS、目标蛋白和短肽AE1。The invention provides a recombinant protein that carries a target protein and enters eukaryotic cells autonomously. The structure of the recombinant protein, from the N-terminus to the C-terminus, includes the nuclear entry signal NLS, the target protein and the short peptide AE1 in sequence.
本发明对利用所述NLS、目标蛋白和AE1构建融合蛋白的方法并没有特殊限定,利用本领域的常规融合蛋白构建方法进行构建即可。本发明所述真核细胞优选包括动物细胞和人类细胞,利用本发明所述结构的重组蛋白,可将目标蛋白送进动物或人类的细胞和细胞核中。本发明实施例中以CPD光解酶为例对所述重组蛋白进行说明,但是不能仅将其认定为本发明的全部保护范围。The present invention has no special limitations on the method of constructing a fusion protein using the NLS, target protein and AE1, and it can be constructed using conventional fusion protein construction methods in the field. The eukaryotic cells of the present invention preferably include animal cells and human cells. Using the recombinant protein with the structure of the present invention, the target protein can be delivered into the cells and nuclei of animals or humans. In the examples of the present invention, CPD photolyase is used as an example to illustrate the recombinant protein, but it cannot be regarded as the entire protection scope of the present invention.
本发明还提供了一种能自主进入人类细胞核修复UV辐射诱发DNA损伤的重组光解酶(实施例也称融合蛋白SVNL::GFP::AE1),所述重组光解酶的结构,从N端至C端,依次包括:来源于SV40病毒的入核信号-CPD光解酶-源于黑腹果蝇的短肽AE1。The present invention also provides a recombinant photolyase that can autonomously enter human cell nuclei to repair DNA damage induced by UV radiation (the embodiment is also called fusion protein SVNL::GFP::AE1). The structure of the recombinant photolyase is from N From end to C end, it includes in sequence: the nuclear entry signal derived from SV40 virus - CPD photolyase - the short peptide AE1 derived from Drosophila melanogaster.
本发明所述入核信号(简称SVNLS)的氨基酸序列优选如SEQ ID NO.1所示:PKKKRKV;所述CPD光解酶优选来源于罗伯茨绿僵菌,其Genbank accession number:XP_007821405;所述短肽AE1的氨基酸序列优选如SEQ ID NO.2所示:GRQIKIWFQNRRMKWKK,具有跨细胞膜能力。本发明所述CPD光解酶的来源除实施例中来源罗伯茨绿僵菌外,还可来源于其他来源,如其他菌株中得到的CPD光解酶或经基因编辑或修饰后的CPD光解酶。The amino acid sequence of the nuclear entry signal (SVNLS for short) of the present invention is preferably as shown in SEQ ID NO.1: PKKKRKV; the CPD photolyase is preferably derived from Metarhizium robertii, its Genbank accession number: XP_007821405; the short The amino acid sequence of peptide AE1 is preferably shown in SEQ ID NO. 2: GRQIKIWFQNRRMKWKK, and has the ability to cross cell membranes. In addition to the source of Metarhizium anisopliae in the examples, the source of the CPD photolytic enzyme of the present invention can also be derived from other sources, such as CPD photolytic enzymes obtained from other strains or CPD photolytic enzymes after gene editing or modification. .
在本发明中,所述DNA损伤优选包括环丁烷嘧啶二聚体(CPD)的DNA损伤,将所述CPD光解酶用AE1送进人类细胞内,并由SVNLS带领进入细胞核内,从而促进外源的CPD光解酶对CPD的DNA损伤进行靶向处理;并提高胞内超氧化物歧化酶(SOD)活性,以及降低胞内氧自由基(ROS)和剧毒分子丙二醛(MDA)水平。In the present invention, the DNA damage preferably includes DNA damage of cyclobutane pyrimidine dimer (CPD). The CPD photolyase is sent into human cells using AE1, and is led into the nucleus by SVNLS, thereby promoting Exogenous CPD photolyase targets DNA damage caused by CPD; increases intracellular superoxide dismutase (SOD) activity, and reduces intracellular oxygen free radicals (ROS) and the highly toxic molecule malondialdehyde (MDA) )level.
本发明还提供了表达上述重组蛋白或上述重组光解酶的重组表达载体,所述重组表达载体包括编码所述重组蛋白或所述重组光解酶的基因。The present invention also provides a recombinant expression vector for expressing the above-mentioned recombinant protein or the above-mentioned recombinant photolyase, and the recombinant expression vector includes a gene encoding the above-mentioned recombinant protein or the above-mentioned recombinant photolyase.
本发明所述重组表达载体的基础载体优选包括pET-28a-sumo载体。本发明对所述重组表达载体的构建方法并没有特殊限定,优选包括:通过PCR方法将SVNLS和AE1分别扩增到所述CPD光解酶的N端和C端;且在进行所述PCR扩增时,上游引物从5’端到3’端,依次包括两个保护碱基GG、限制性内切酶BamHI的识别位点、SVNLS的编码序列和CPD光解酶编码序列起始的17个碱基。下游引物从5’端到3’端,依次包括两个保护碱基GG、限制性内切酶XbaI的识别位点、短肽AE1的编码序列和罗伯茨绿僵菌光解酶编码序列最后17个碱基(不含终止密码子);所得产物克隆进大肠杆菌表达载体pET-28a-sumo。在本发明实施例中,针对所述PCR扩增所设计的引物优选包括:上游引物SVNLS-MrPHR1-5(SEQ ID NO.3):CGGGATCCATGCCAAAAAAGAAGAGAAAGGTCAGTCCTGACCACACCAACG;下游引物AE1-MrPHR1-3(SEQ ID NO.4):CGGAATTCTTATCATTTTTTCCATTTCATGCGGCGGTTCTGAAACCAAATTTTAATCTGGCGGCCCATGCCATTGGCGATTCC。The basic vector of the recombinant expression vector of the present invention preferably includes the pET-28a-sumo vector. The present invention has no special limitation on the construction method of the recombinant expression vector, which preferably includes: amplifying SVNLS and AE1 to the N-terminal and C-terminal of the CPD photolyase respectively by PCR method; and performing the PCR amplification When increasing, the upstream primer sequentially includes two protective bases GG from the 5' end to the 3' end, the recognition site of the restriction endonuclease BamHI, the coding sequence of SVNLS and the 17 starting points of the CPD photolyase coding sequence. base. From the 5' end to the 3' end, the downstream primer includes two protective bases GG, the recognition site of the restriction endonuclease XbaI, the coding sequence of the short peptide AE1, and the last 17 coding sequences of Metarhizium anisopliae photolyase. base (excluding stop codon); the resulting product was cloned into the E. coli expression vector pET-28a-sumo. In the embodiment of the present invention, the primers designed for the PCR amplification preferably include: upstream primer SVNLS-MrPHR1-5 (SEQ ID NO.3): CGGGATCCATGCCAAAAAAGAAGAGAAAGGTCAGTCCTGACCACACCAACG; downstream primer AE1-MrPHR1-3 (SEQ ID NO.4 ): CGGAATTCTTATCATTTTTTTCCATTTCATGCGGCGGTTCTGAAACCAAATTTTAATCTGGCGGCCCATGCCATTGGCGATTCC.
本发明还提供了表达上述重组蛋白或上述重组光解酶的重组菌,所述重组菌的基因组中包括编码所述重组蛋白或所述重组光解酶的基因或上述重组表达载体。The present invention also provides a recombinant bacterium expressing the above recombinant protein or the above recombinant photolyase, and the genome of the recombinant bacterium includes a gene encoding the recombinant protein or the above recombinant photolyase or the above recombinant expression vector.
本发明所述重组菌的基础菌株优选包括大肠杆菌,实施例中以大肠杆菌BL21菌株为例进行说明,但是不能仅将其认定为本发明的全部保护范围。本发明对所述重组菌的构建方法并没有特殊限定,优选利用上述重组表达载体转化大肠杆菌BL21菌株,得到表达生产上述重组光解酶的大肠杆菌重组菌株。The basic strain of the recombinant bacteria of the present invention preferably includes Escherichia coli. In the embodiment, Escherichia coli BL21 strain is used as an example for explanation, but it cannot be regarded as the entire protection scope of the present invention. The present invention has no particular limitation on the construction method of the recombinant bacteria. It is preferred to use the above recombinant expression vector to transform the Escherichia coli BL21 strain to obtain the Escherichia coli recombinant strain that expresses and produces the above recombinant photolyase.
本发明还提供了利用上述重组菌制备所述重组光解酶的方法,优选包括:将上述重组菌的单菌落接种到5mL含卡那霉素的LB液体培养基中进行培养,得种子液;将种子液接种到含卡那霉素的LB液体培养基中再次培养,利用IPTG诱导,然后于18℃培养12h,收集菌体并破碎,离心收集蛋白粗提液,蛋白粗提液中包含所述重组光解酶。The present invention also provides a method for preparing the recombinant photolytic enzyme using the above recombinant bacteria, which preferably includes: inoculating a single colony of the above recombinant bacteria into 5 mL of LB liquid culture medium containing kanamycin and culturing it to obtain a seed liquid; The seed liquid was inoculated into LB liquid medium containing kanamycin and cultured again, induced by IPTG, and then cultured at 18°C for 12 hours. The bacterial cells were collected and broken, and the crude protein extract was collected by centrifugation. The crude protein extract contained all the The recombinant photolyase enzyme.
在本发明中,所述LB液体培养基中卡那霉素的浓度优选均为100μg/mL;利用含卡那霉素的LB培养基进行所述培养时优选在摇床上进行,所述培养的温度优选为37℃,220rpm。In the present invention, the concentration of kanamycin in the LB liquid culture medium is preferably 100 μg/mL; the culture using the LB culture medium containing kanamycin is preferably carried out on a shaking table. The temperature is preferably 37°C, 220 rpm.
在本发明实施例中,优选取100μL的种子液接种到1000mL的含卡那霉素的LB液体培养基中再次培养,待OD600值达到0.6时,于培养液中加入IPTG进行诱导,所述IPTG的添加终浓度优选为0.8mmol/L。本发明对18℃培养12h后的菌体收集并破碎的方法并没有特殊限定,利用本领域的常规方法收集菌体,破碎细胞,并通过离心获得蛋白粗提液。In the embodiment of the present invention, it is preferred to inoculate 100 μL of seed liquid into 1000 mL of kanamycin-containing LB liquid medium and culture it again. When the OD 600 value reaches 0.6, IPTG is added to the culture medium for induction. The final concentration of IPTG added is preferably 0.8mmol/L. The present invention does not specifically limit the method of collecting and disrupting the bacterial cells after culturing at 18°C for 12 hours. Conventional methods in the field are used to collect the bacterial cells, disrupt the cells, and obtain a crude protein extract through centrifugation.
本发明在得到所述蛋白粗提液后,优选还包括纯化,更优选的包括将所述蛋白粗提液过镍柱,以将带6个组氨酸的SUMO标签标记的重组光解酶吸附在镍柱上;将镍柱上的蛋白洗脱后用ULP1蛋白酶处理以切除带6个组氨酸的SUMO标签,并进一步过镍柱和脱盐后,得到纯化后的重组光解酶。After obtaining the crude protein extract, the present invention preferably further includes purification, and more preferably includes passing the crude protein extract through a nickel column to adsorb the recombinant photolyase labeled with a SUMO tag of 6 histidines. On the nickel column; the protein on the nickel column is eluted and treated with ULP1 protease to remove the SUMO tag with 6 histidines, and is further passed through the nickel column and desalted to obtain the purified recombinant photolyase.
本发明还提供了上述重组光解酶在制备用于治疗UV辐射诱发的环丁烷嘧啶二聚体的DNA损伤的药物中的应用。在本发明实施例中,利用所述重组光解酶,可以成功入核修复由于紫外辐射产生的CPD损伤。The present invention also provides the application of the above-mentioned recombinant photolyase in preparing a drug for treating DNA damage of cyclobutane pyrimidine dimers induced by UV radiation. In embodiments of the present invention, the recombinant photolyase can be used to successfully enter the nucleus and repair CPD damage caused by ultraviolet radiation.
下面结合实施例对本发明提供的一种携带目标蛋白自主进入真核细胞的重组蛋白、重组表达载体和重组菌及应用进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。The recombinant protein, recombinant expression vector and recombinant bacteria provided by the present invention that carry the target protein into eukaryotic cells autonomously and their applications will be described in detail below with reference to the examples. However, they should not be understood as limiting the scope of the present invention.
实施例1Example 1
SVNLS和AE1将外源蛋白GFP带入细胞核的能力分析Analysis of the ability of SVNLS and AE1 to bring foreign protein GFP into the nucleus
1)SVNLS::GFP::AE1蛋白表达载体的构建及原核表达。1) Construction and prokaryotic expression of SVNLS::GFP::AE1 protein expression vector.
在用PCR克隆绿色荧光蛋白GFP编码序列时将SVNLS和AE1的编码序列分别接在GFP蛋白的N-端和C-端(其中GFP编码序列中的终止密码子被除去,并在SVNLS的前面添加一个翻译起始密码子ATG)。When cloning the green fluorescent protein GFP coding sequence using PCR, the coding sequences of SVNLS and AE1 were connected to the N-terminus and C-terminus of the GFP protein respectively (the stop codon in the GFP coding sequence was removed and added in front of SVNLS A translation initiation codon (ATG).
PCR扩增所用上游引物SVNLS-GFP-5(SEQ ID NO.5):CGGGATCCATGCCAAAAAAGAAGAGAAAGGTCGTGAGCAAGGGCGAGGA;下游引物AE1-GFP-3(SEQ ID NO.6):CGGAATTCTTATCATTTTTTCCATTTCATGCGGCGGTTCTGAAACCAAATTTTAATCTGGCGGCCCTTGTACAGCTCGTCCA。以含GFP编码序列的DNA片段为模板,PCR扩增体系(总体积50μL)为:ddH2O 15μL,2×Phanta Max buffer(Vazyme)25μL,dNTP Mix(10μM each,Vazyme)1μL,SVNLS-GFP-52μL(10μM),AE1-GFP-32μL(10μM),Phanta Max Super-Fidelity DNApolymerase(Vazyme)1μL,DNA片段模板(GFP)2μL。反应程序为:95℃3min→(95℃15sec→56~72℃15sec→72℃1min/kb)循环30次→72℃5min。The upstream primer SVNLS-GFP-5 (SEQ ID NO. 5) used for PCR amplification: CGGGATCCATGCCAAAAAAGAAGAGAAAGGTCGTGAGCAAGGGCGAGGA; the downstream primer AE1-GFP-3 (SEQ ID NO. 6): CGGAATTCTTATCATTTTTTCCATTTCATGCGGCGGTTCTGAAACCAAATTTTAATCTGGCGGCCCTTGTACAGCTCGTCCA. Using the DNA fragment containing the GFP coding sequence as the template, the PCR amplification system (total volume 50 μL) is: ddH 2 O 15 μL, 2× Phanta Max buffer (Vazyme) 25 μL, dNTP Mix (10 μM each, Vazyme) 1 μL, SVNLS-GFP -52μL (10μM), AE1-GFP-32μL (10μM), Phanta Max Super-Fidelity DNApolymerase (Vazyme) 1μL, DNA fragment template (GFP) 2μL. The reaction program is: 95°C 3min → (95°C 15sec → 56~72°C 15sec → 72°C 1min/kb) cycle 30 times → 72°C 5min.
PCR产物连接到载体pET-28a-sumo的BamH I和EcoR I位点,测序验证无突变后得到蛋白SVNLS::GFP::AE1的原核表达载体pET-28a-sumo-SVNLS-GFP-AE1,并转入大肠杆菌BL21菌株中。The PCR product was connected to the BamH I and EcoR I sites of the vector pET-28a-sumo. After sequencing to verify that there were no mutations, the prokaryotic expression vector pET-28a-sumo-SVNLS-GFP-AE1 of the protein SVNLS::GFP::AE1 was obtained, and into Escherichia coli BL21 strain.
大肠杆菌BL21菌株表达SVNLS::GFP::AE1蛋白由IPTG诱导,将一个重组大肠杆菌菌株菌落接种到5mL含卡那霉素的LB液体培养基,于37℃培养过夜后,取100μL菌液到1000mL的含卡那霉素的LB液体培养基中,再次于37℃培养到菌液OD600值达到0.6左右,然后于培养液中加入IPTG(终浓度为0.8mmol/L)。18℃继续培养12h以表达重组蛋白。SDS-PAGE分析表明,SVNLS::GFP::AE1蛋白被成功表达,并存在于提取液的上清液中如图2所示。Escherichia coli BL21 strain expresses SVNLS::GFP::AE1 protein induced by IPTG. Inoculate a colony of the recombinant Escherichia coli strain into 5 mL of LB liquid medium containing kanamycin. After culturing overnight at 37°C, take 100 μL of the bacterial liquid into In 1000 mL of LB liquid medium containing kanamycin, culture again at 37°C until the OD 600 value of the bacterial solution reaches about 0.6, and then add IPTG (final concentration: 0.8 mmol/L) to the culture medium. Culture was continued for 12 h at 18°C to express the recombinant protein. SDS-PAGE analysis showed that the SVNLS::GFP::AE1 protein was successfully expressed and existed in the supernatant of the extract as shown in Figure 2.
2)蛋白纯化具体过程:2) Specific process of protein purification:
①按上述方法诱导表达SVNLS::GFP::AE1后,4℃,4500rpm离心20min收集细胞。使用pH 7.0的lysis buffer重悬菌体细胞,并超声破碎25min(70kHz)。破碎完成后于4℃,12000rpm离心60min。分别收集破碎液、上清液和沉淀进行SDS-PAGE分析,检测目的蛋白是否大量表达。① After inducing the expression of SVNLS::GFP::AE1 according to the above method, centrifuge at 4°C and 4500rpm for 20 minutes to collect the cells. Use lysis buffer with pH 7.0 to resuspend the bacterial cells and sonicate for 25 minutes (70kHz). After the crushing is completed, centrifuge at 4°C and 12,000 rpm for 60 min. Collect the broken fluid, supernatant and precipitate separately for SDS-PAGE analysis to detect whether the target protein is expressed in large amounts.
②将上清液即蛋白粗提液过镍柱,带6个组氨酸的SUMO标签标记的目的蛋白吸附在镍柱上,使用pH 7.0的washbuffer洗去镍柱上的杂蛋白,再用pH7.0的elute buffer洗脱目的蛋白。洗脱下的目的蛋白用5mg ULP1蛋白酶处理以切除带6个组氨酸的SUMO标签,酶切过夜后使用Amino Ultra-15(10kDa)超滤管离心浓缩蛋白至15mL。将15mL浓缩液再次过镍柱,除去ULP1和sumo标签。使用Amino Ultra-15(10kDa)超滤管离心浓缩,并用pH 7.0的脱盐buffer除去咪唑。最后获得50mg的蛋白(体积为5mL左右),加入10%的甘油,利用0.2μm的滤膜过滤除菌,分装后于-80℃保存。② Pass the supernatant, that is, the crude protein extract, through the nickel column. The target protein labeled with the SUMO tag of 6 histidines is adsorbed on the nickel column. Use a pH 7.0 washbuffer to wash away the impurity proteins on the nickel column, and then use pH 7. Elute the target protein with .0 elute buffer. The eluted target protein was treated with 5 mg of ULP1 protease to remove the SUMO tag with 6 histidines. After overnight digestion, the protein was centrifuged using an Amino Ultra-15 (10 kDa) ultrafiltration tube to concentrate the protein to 15 mL. Pass 15 mL of the concentrated solution through the nickel column again to remove ULP1 and sumo tags. Use Amino Ultra-15 (10kDa) ultrafiltration tube to concentrate by centrifugation, and use pH 7.0 desalting buffer to remove imidazole. Finally, 50 mg of protein (volume of about 5 mL) was obtained, 10% glycerol was added, sterilized by filtration with a 0.2 μm filter, and stored at -80°C after aliquots.
3)SVNLS::GFP::AE1进入HFF-1细胞能力分析3) Analysis of the ability of SVNLS::GFP::AE1 to enter HFF-1 cells
人皮肤成纤维细胞HFF-1在直径100mm培养皿培养4天后,经胰蛋白酶处理后,收集细胞并重悬在1mL的细胞培养基中。然后将100μL上述细胞悬液接种到含2mL培养基的直径为30mm的培养皿中。于37℃培养3-4天后,向细胞培养基中添加过滤除菌的SVNLS::GFP::AE1蛋白(终浓度为100ng/μL),另设一组添加GFP蛋白作为对照。于37℃培养箱中孵育12h后,倒去培养基,并用1×PBS轻轻冲洗3遍除去细胞表面残留蛋白后用于后续实验。Human skin fibroblast HFF-1 was cultured in a 100 mm diameter culture dish for 4 days. After trypsin treatment, the cells were collected and resuspended in 1 mL of cell culture medium. Then 100 μL of the above cell suspension was inoculated into a 30 mm diameter culture dish containing 2 mL of culture medium. After culturing at 37°C for 3-4 days, filter-sterilized SVNLS::GFP::AE1 protein (final concentration: 100ng/μL) was added to the cell culture medium, and another group was set up to add GFP protein as a control. After incubation in a 37°C incubator for 12 hours, the culture medium was poured out, and gently washed three times with 1×PBS to remove residual proteins on the cell surface before use in subsequent experiments.
①SVNLS::GFP::AE1入细胞验证①Verification of SVNLS::GFP::AE1 entering cells
上述HFF-1细胞与SVNLS::GFP::AE1蛋白孵育12h后,用胰蛋白酶消化处理,并用流式细胞仪检测收集的细胞以分析上述蛋白进入细胞的情况及胞内GFP荧光强度。结果如图3所示,与SVNLS::GFP::AE1蛋白共孵育的HFF-1细胞内GFP荧光强度高于与GFP蛋白共孵育的HFF-1细胞,说明SVNLS::GFP::AE1蛋白与未携带SVNLS和AE1的GFP蛋白相比具有强的进入细胞的能力。After the above-mentioned HFF-1 cells were incubated with SVNLS::GFP::AE1 protein for 12 hours, they were digested with trypsin, and the collected cells were detected by flow cytometry to analyze the entry of the above-mentioned protein into the cells and the intracellular GFP fluorescence intensity. The results are shown in Figure 3. The fluorescence intensity of GFP in HFF-1 cells co-incubated with SVNLS::GFP::AE1 protein was higher than that in HFF-1 cells co-incubated with GFP protein, indicating that SVNLS::GFP::AE1 protein and Compared with the GFP protein without SVNLS and AE1, it has a stronger ability to enter cells.
②SVNLS::GFP::AE1入细胞核验证②Verification of SVNLS::GFP::AE1 entering the cell nucleus
上述HFF-1细胞与SVNLS::GFP::AE1共孵育12h后,倒去细胞培养基,向培养皿中添加1mL 2μg/mL DAPI染色液(染色细胞核)覆盖细胞,室温避光放置5min,吸去DAPI染色液,用1×PBS洗涤3次,每次5min。封片后利用荧光显微镜观察,荧光观察结果如图4所示,绿色荧光显示的是转运至细胞内的SVNLS::GFP::AE1蛋白,蓝色荧光显示位置是HFF-1细胞的细胞核,图中显示绿色荧光与蓝色荧光重合,则说明SVNLS::GFP::AE1成功进入HFF-1的细胞核。After the above HFF-1 cells were incubated with SVNLS::GFP::AE1 for 12 hours, the cell culture medium was poured out, and 1 mL of 2 μg/mL DAPI staining solution (stained cell nuclei) was added to the culture dish to cover the cells. Leave it at room temperature for 5 minutes in the dark and aspirate. Remove the DAPI staining solution and wash 3 times with 1×PBS for 5 minutes each time. After sealing, use a fluorescence microscope to observe. The fluorescence observation results are shown in Figure 4. The green fluorescence shows the SVNLS::GFP::AE1 protein transported into the cells, and the blue fluorescence shows the nucleus of HFF-1 cells. Figure The green fluorescence and blue fluorescence overlap, indicating that SVNLS::GFP::AE1 successfully entered the nucleus of HFF-1.
实施例2Example 2
重组蛋白SVNLS::MrPHR1::AE1的表达与制备Expression and preparation of recombinant protein SVNLS::MrPHR1::AE1
为了利用SVNLS和AE1短肽将罗伯茨绿僵菌的CPD光解酶(MAA_05216,命名为MrPHR1)带入哺乳动物细胞核并修复核DNA上的CPD损伤,本发明构建了融合蛋白SVNLS::MrPHR1::AE1。In order to use SVNLS and AE1 short peptides to bring the CPD photolyase of Metarhizium anisopliae (MAA_05216, named MrPHR1) into mammalian cell nuclei and repair CPD damage on nuclear DNA, the present invention constructed the fusion protein SVNLS::MrPHR1:: AE1.
为此,在用PCR克隆MrPHR1编码序列(Genbank accession number:XP_007821405)时将SVNLS和AE1的编码序列分别接在MrPHR1蛋白的N-端和C-端(其中MrPHR1编码序列中的终止密码子被除去,并在SVNLS的前面添加一个翻译起始密码子ATG)。所用引物为SEQ IDNO.3和SEQ ID NO.4,模板为罗伯茨绿僵菌菌丝体的cDNA。扩增体系和扩增程序同实施例1,其中扩增体系中的上下引物变为SEQ ID NO.3和SEQ ID NO.4。To this end, when cloning the MrPHR1 coding sequence (Genbank accession number: , and add a translation initiation codon ATG) in front of SVNLS. The primers used were SEQ ID NO.3 and SEQ ID NO.4, and the template was the cDNA of Metarhizium anisopliae mycelium. The amplification system and amplification procedure are the same as in Example 1, except that the upper and lower primers in the amplification system are changed to SEQ ID NO.3 and SEQ ID NO.4.
PCR产物连接到载体pET-28a-sumo的BamH I和EcoR I位点,测序验证无突变后得到SVNLS::MrPHR1::AE1的原核表达载体pET-28a-sumo-SVNLS-MrPHR1-AE1,并转入大肠杆菌BL21菌株中。The PCR product was connected to the BamH I and EcoR I sites of the vector pET-28a-sumo. After sequencing to verify that there were no mutations, the prokaryotic expression vector pET-28a-sumo-SVNLS-MrPHR1-AE1 of SVNLS::MrPHR1::AE1 was obtained and transformed into Escherichia coli strain BL21.
大肠杆菌BL21菌株中SVNLS::MrPHR1::AE1蛋白的IPTG诱导表达和纯化同实施例1。SDS-PAGE分析结果如图5所示,SVNLS::MrPHR1::AE1蛋白被成功表达和纯化。The IPTG-induced expression and purification of SVNLS::MrPHR1::AE1 protein in E. coli BL21 strain are the same as in Example 1. The SDS-PAGE analysis results are shown in Figure 5. The SVNLS::MrPHR1::AE1 protein was successfully expressed and purified.
利用相同的方法,构建用于作对照的蛋白MrPHR1::AE1和SVNLS::MrPHR1。构建方法除扩增引物不同外,其余均与实施例2相同;Using the same method, the control proteins MrPHR1::AE1 and SVNLS::MrPHR1 were constructed. The construction method is the same as Example 2 except for the different amplification primers;
其中构建蛋白MrPHR1::AE1所用上游引物MrPHR1-5(SEQ ID NO.7)的序列为CGGGATCCATGGCTCGAAAATCATCG;下游引物AE1-MrPHR1-3(SEQ ID NO.4)的序列同上。The sequence of the upstream primer MrPHR1-5 (SEQ ID NO.7) used to construct the protein MrPHR1::AE1 is CGGGATCCATGGCTCGAAAATCATCG; the sequence of the downstream primer AE1-MrPHR1-3 (SEQ ID NO.4) is the same as above.
构建蛋白SVNLS::MrPHR1所用上游引物SVNLS-MrPHR1-5的序列同上(SEQ IDNO.3);下游引物MrPHR1-3(SEQ ID NO.8)的序列为CGGAATTCCTACATGCCATTGGCGA。The sequence of the upstream primer SVNLS-MrPHR1-5 used to construct the protein SVNLS::MrPHR1 is the same as above (SEQ ID NO.3); the sequence of the downstream primer MrPHR1-3 (SEQ ID NO.8) is CGGAATTCCTACATGCCATTGGCGA.
利用上述相同方法进行原核表达实验,SDS-PAGE分析结果如图6所示,MrPHR1::AE1及SVNLS::MrPHR1蛋白被成功表达和纯化。Prokaryotic expression experiments were performed using the same method as above. The SDS-PAGE analysis results are shown in Figure 6. MrPHR1::AE1 and SVNLS::MrPHR1 proteins were successfully expressed and purified.
实施例3Example 3
SVNLS::MrPHR1::AE1入细胞核后修复DNA CPD损伤能力分析Analysis of the ability of SVNLS::MrPHR1::AE1 to repair DNA CPD damage after entering the nucleus
1)光修复UV处理的HFF-1细胞1) Photorepair of UV-treated HFF-1 cells
(1)细胞培养和处理设置(1) Cell culture and processing settings
HFF-1细胞传代至直径30mm的Corning培养皿中,在二氧化碳培养箱内于37℃培养3天后进行如下处理:不做任何处理的阴性对照(未处理),细胞与重组蛋白共孵育(Cell+protein)、UV辐射细胞(UV/cell),可见光照射UV处理过的细胞(Light+UV/cell)、与重组蛋白共孵育的细胞用UV辐射处理(UV+protein/cell)、与重组蛋白共孵育的细胞经UV辐射后用可见光处理(Light+UV+protein/cell),每个设置3个重复。HFF-1 cells were passaged into Corning culture dishes with a diameter of 30 mm, cultured in a carbon dioxide incubator at 37°C for 3 days, and then processed as follows: negative control without any treatment (untreated), cells co-incubated with recombinant protein (Cell+ protein), UV irradiated cells (UV/cell), visible light irradiated UV-treated cells (Light+UV/cell), cells incubated with recombinant proteins treated with UV irradiation (UV+protein/cell), cells co-incubated with recombinant proteins The incubated cells were UV irradiated and then treated with visible light (Light+UV+protein/cell), with 3 replicates for each setting.
对于与重组蛋白共孵育的细胞经UV辐射后用可见光处理(Light+UV+protein/cell)这个设置中,重组蛋白有4种(SVNLS::MrPHR1::AE1,SVNLS::MrPHR1,MrPHR1::AE1或SVNLS::GFP::AE1),在其它设置中重组蛋白仅为SVNLS::MrPHR1::AE1。For cells co-incubated with recombinant proteins, they are treated with visible light after UV irradiation (Light+UV+protein/cell). In this setting, there are 4 types of recombinant proteins (SVNLS::MrPHR1::AE1, SVNLS::MrPHR1, MrPHR1:: AE1 or SVNLS::GFP::AE1), in other settings the recombinant protein was only SVNLS::MrPHR1::AE1.
重组蛋白在细胞培养60h后加入到细胞培养基中(蛋白终浓度为100ng/mL),于37℃继续培养12h后,进行后续处理。UV处理的剂量1J/m2。The recombinant protein was added to the cell culture medium after the cells were cultured for 60 hours (the final protein concentration was 100ng/mL), and the culture was continued for 12 hours at 37°C before subsequent treatment. The dose of UV treatment is 1J/m 2 .
可见光处理过程为:在细胞培养皿上放一块玻璃片(过滤UV和减少培养基蒸发),在37℃的二氧化碳培养箱用可见光照射3h(光源为10W的日光灯管)。处理后的细胞取出用PBS洗3遍后,分别收集细胞至1.5mL Ep管中。The visible light treatment process is as follows: place a glass piece on the cell culture dish (to filter UV and reduce evaporation of the culture medium), and irradiate it with visible light for 3 hours in a carbon dioxide incubator at 37°C (the light source is a 10W fluorescent tube). The treated cells were taken out and washed three times with PBS, and then collected into 1.5 mL Ep tubes.
(2)提取不同条件处理的HFF-1细胞基因组DNA:(2) Extract genomic DNA from HFF-1 cells treated with different conditions:
将上述细胞收集进Ep管中,每管中加入200μL的DNA提取液(0.2M pH7.5 Tris,0.5MNaCl,0.01M PH8.0 EDTA,1%SDS),充分涡旋,再加入200μL的氯仿(pH 7.0)充分涡旋,14000rpm室温离心8min,取上清液至新的Ep管中,向各管加1.5μLRNase,37℃孵育1h。再加200μL的氯仿(pH 7.0)充分涡旋抽提一次,14000rpm室温离心8min,取上清液至新的Ep管中。加入500μL无水乙醇,充分涡旋后将Ep管置于-20℃沉淀30min,14000rpm室温离心5min后去上清。添加700μL 75%乙醇,充分涡旋后14000rpm室温离心2min后去上清,Ep管开盖置于37℃烘箱中5min,使Ep管内乙醇完全挥发。添加30μL无菌水充分涡旋溶解沉淀,所得液体即为HFF-1细胞基因组DNA。用吸光度法测定DNA浓度。Collect the above cells into Ep tubes, add 200 μL of DNA extraction solution (0.2M pH7.5 Tris, 0.5M NaCl, 0.01M pH8.0 EDTA, 1% SDS) to each tube, vortex thoroughly, and then add 200 μL of chloroform (pH 7.0) Vortex thoroughly, centrifuge at 14000 rpm for 8 min at room temperature, transfer the supernatant to a new Ep tube, add 1.5 μL RNase to each tube, and incubate at 37°C for 1 h. Add 200 μL of chloroform (pH 7.0), vortex thoroughly for extraction once, centrifuge at 14,000 rpm for 8 min at room temperature, and transfer the supernatant to a new Ep tube. Add 500 μL of absolute ethanol, vortex thoroughly, place the Ep tube at -20°C for precipitation for 30 minutes, centrifuge at 14,000 rpm for 5 minutes at room temperature, and then remove the supernatant. Add 700 μL of 75% ethanol, vortex thoroughly, centrifuge at room temperature at 14,000 rpm for 2 min, and then remove the supernatant. Open the cap of the Ep tube and place it in a 37°C oven for 5 min to completely evaporate the ethanol in the Ep tube. Add 30 μL of sterile water and vortex thoroughly to dissolve the precipitate. The resulting liquid is HFF-1 cell genomic DNA. Determine DNA concentration using absorbance method.
2)ELISA分析DNA中CPD含量:2) ELISA analysis of CPD content in DNA:
(1)制备鱼精蛋白预处理的96孔板。将50μL/孔的无菌0.003%(w/v)鱼精蛋白硫酸盐溶液加入到每个孔中,37℃过夜烘干,再用100μL的ddH2O清洗3次后,避光存放。(1) Prepare a protamine-pretreated 96-well plate. Add 50 μL/well of sterile 0.003% (w/v) protamine sulfate solution to each well, dry at 37°C overnight, wash three times with 100 μL of ddH 2 O, and store in the dark.
(2)CPD含量测定。测定过程按照CPD antibody(Cosmo Bio Co.LTD.Japan)的说明书进行。DNA浓度为50ng/μL。(图7)(2) CPD content determination. The measurement process was carried out according to the instructions of CPD antibody (Cosmo Bio Co. LTD. Japan). The DNA concentration is 50ng/μL. (Figure 7)
(3)结果。与阴性对照相比,HFF-1经UV照射后细胞内CPD含量上升约150倍,再将内含UV损伤的HFF-1进行可见光照射后发现,只有SVNLS::MrPHR1::AE1重组蛋白孵育和可见光照射处理的细胞内CPD含量降低35%,而另外3种重组蛋白(SVNLS::MrPHR1,MrPHR1::AE1和SVNLS::GFP::AE1)对细胞内CPD含量无明显影响。说明SVNLS::MrPHR1::AE1可以成功入核修复由于紫外辐射产生的CPD损伤。(3) Results. Compared with the negative control, the intracellular CPD content of HFF-1 increased approximately 150 times after UV irradiation. After irradiating the UV-damaged HFF-1 with visible light, it was found that only the SVNLS::MrPHR1::AE1 recombinant protein incubated and The CPD content in cells treated with visible light irradiation decreased by 35%, while the other three recombinant proteins (SVNLS::MrPHR1, MrPHR1::AE1 and SVNLS::GFP::AE1) had no significant effect on the CPD content in cells. This shows that SVNLS::MrPHR1::AE1 can successfully enter the nucleus and repair CPD damage caused by ultraviolet radiation.
实施例4Example 4
SVNLS::MrPHR1::AE1入细胞核后降低胞内氧自由基(ROS)水平SVNLS::MrPHR1::AE1 reduces intracellular oxygen free radicals (ROS) levels after entering the cell nucleus.
1)光修复UV辐射的HFF-1细胞1) Photorepair of UV-irradiated HFF-1 cells
(1)细胞培养和处理设置。(同实施例3)(1) Cell culture and processing settings. (Same as Example 3)
(2)细胞样品处理。细胞用一定量的PBS重悬使其浓度为2×107cells/mL。取600μL2×107cells/mL的细胞悬液至1.5mL Ep管中,超声破碎3min(70kHZ)。破碎完成后于4℃,12000rpm离心10min,收集上清液,置于冰上待测。(2) Cell sample processing. The cells were resuspended in a certain amount of PBS to a concentration of 2×10 7 cells/mL. Take 600 μL of cell suspension of 2×10 7 cells/mL into a 1.5 mL Ep tube, and sonicate for 3 min (70 kHZ). After the crushing is completed, centrifuge at 4°C and 12,000 rpm for 10 min. Collect the supernatant and place it on ice for testing.
2)ROS含量测定:测定过程按照Oxiselect in vitro ROS/RNS assay kit(CellBiolabs,USA)试剂盒说明书进行。2) ROS content determination: The determination process was carried out according to the instructions of the Oxiselect in vitro ROS/RNS assay kit (CellBiolabs, USA).
3)结果。与阴性对照细胞相比,UV辐射使HFF-1细胞内ROS水平上升2.3倍。再将内含UV损伤的HFF-1进行可见光照射后发现,只有SVNLS::MrPHR1::AE1重组蛋白孵育的细胞经可见光照射后细胞内ROS水平下降到与阴性对照细胞相当的水平;而另外2种重组蛋白(SVNLS::MrPHR1,MrPHR1::AE1)对细胞内ROS水平无影响。说明SVNLS::MrPHR1::AE1清除了UV辐射诱发的ROS(图8)。3) Results. Compared with negative control cells, UV radiation increased ROS levels in HFF-1 cells by 2.3 times. After irradiating the UV-damaged HFF-1 with visible light, it was found that only the cells incubated with the SVNLS::MrPHR1::AE1 recombinant protein had intracellular ROS levels that dropped to a level comparable to that of the negative control cells after visible light irradiation; while the other 2 cells The two recombinant proteins (SVNLS::MrPHR1, MrPHR1::AE1) had no effect on intracellular ROS levels. It shows that SVNLS::MrPHR1::AE1 scavenges ROS induced by UV radiation (Figure 8).
实施例5Example 5
SVNLS::MrPHR1::AE1入细胞核后降低胞内毒性物质丙二醛(MDA)水平SVNLS::MrPHR1::AE1 reduces the level of the intracellular toxic substance malondialdehyde (MDA) after entering the cell nucleus.
1)光修复UV处理的HFF-1细胞1) Photorepair of UV-treated HFF-1 cells
(1)细胞培养和处理设置。(同实施例3)(1) Cell culture and processing settings. (Same as Example 3)
(2)细胞样品处理。收集5×107个细胞至1.5mL Ep管中,加入1mL提取液(下述试剂盒提供)涡旋混匀,超声破碎3min(70kHZ)。破碎完成后于4℃,12000rpm离心10min,收集上清液,置于冰上待测。(2) Cell sample processing. Collect 5×10 7 cells into a 1.5mL Ep tube, add 1mL of extraction solution (provided by the kit below), vortex and mix, and sonicate for 3 minutes (70kHZ). After the crushing is completed, centrifuge at 4°C and 12,000 rpm for 10 min. Collect the supernatant and place it on ice for testing.
2)MDA含量测定:测定过程按照丙二醛(MDA)含量检测试剂盒(Solarbio,中国)说明书进行。2) MDA content determination: The determination process was carried out according to the instructions of the malondialdehyde (MDA) content detection kit (Solarbio, China).
3)结果。与阴性对照细胞相比,UV辐射使HFF-1细胞内MDA含量上升5.4倍。再将内含UV损伤的HFF-1进行可见光照射后发现,只有SVNLS::MrPHR1::AE1重组蛋白孵育的细胞经可见光照射后细胞内MDA水平下降51%。另外2种重组蛋白(SVNLS::MrPHR1,MrPHR1::AE1)对细胞内MDA水平无影响。说明SVNLS::MrPHR1::AE1清除了UV辐射所诱发的MDA(图9)。3) Results. Compared with negative control cells, UV radiation increased the MDA content in HFF-1 cells by 5.4 times. After irradiating the UV-damaged HFF-1 with visible light, it was found that only cells incubated with the SVNLS::MrPHR1::AE1 recombinant protein had a 51% decrease in intracellular MDA levels after visible light irradiation. The other two recombinant proteins (SVNLS::MrPHR1, MrPHR1::AE1) had no effect on intracellular MDA levels. This shows that SVNLS::MrPHR1::AE1 clears MDA induced by UV radiation (Figure 9).
实施例6Example 6
SVNLS::MrPHR1::AE1入细胞核后增加胞内超氧化物歧化酶SOD活性SVNLS::MrPHR1::AE1 increases intracellular superoxide dismutase SOD activity after entering the cell nucleus.
1)光修复UV处理的HFF-1细胞1) Photorepair of UV-treated HFF-1 cells
(1)细胞培养和处理设置。(同实施例3)(1) Cell culture and processing settings. (Same as Example 3)
(2)细胞样品处理。(同实施例5)(2) Cell sample processing. (Same as Example 5)
2)SOD活力测定:测定过程按照超氧化物歧化酶(SOD)活性检测试剂盒(Solarbio,中国)说明书进行。2) SOD activity measurement: The measurement process was carried out according to the instructions of the superoxide dismutase (SOD) activity detection kit (Solarbio, China).
3)结果。阴性对照的HFF-1细胞内SOD酶活性处于较低水平,UV辐射使其中的SOD活性上升2.7倍。再将内含UV损伤的HFF-1进行可见光照射后发现,只有SVNLS::MrPHR1::AE1重组蛋白孵育的细胞经可见光照射处理的细胞内SOD酶活性进一步上升,达到阴性对照的4倍。另外2种重组蛋白(SVNLS::MrPHR1,MrPHR1::AE1)对细胞内SOD酶活性无影响(图10),表明SVNLS::MrPHR1::AE1能提高细胞内的SOD酶活性,这可能是该重组蛋白能降低这类细胞内ROS水平的一个原因。3) Results. The SOD enzyme activity in the negative control HFF-1 cells was at a low level, and UV radiation increased the SOD activity by 2.7 times. After irradiating the UV-damaged HFF-1 with visible light, it was found that only the SOD enzyme activity in the cells incubated with the SVNLS::MrPHR1::AE1 recombinant protein further increased after visible light irradiation treatment, reaching 4 times that of the negative control. The other two recombinant proteins (SVNLS::MrPHR1, MrPHR1::AE1) have no effect on intracellular SOD enzyme activity (Figure 10), indicating that SVNLS::MrPHR1::AE1 can increase intracellular SOD enzyme activity, which may be the reason for this. One reason why recombinant proteins can reduce ROS levels in such cells.
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。The above are only preferred embodiments of the present invention. It should be noted that those skilled in the art can make several improvements and modifications without departing from the principles of the present invention. These improvements and modifications can also be made. should be regarded as the protection scope of the present invention.
序列表 sequence list
<110> 浙江大学<110> Zhejiang University
<120> 一种携带目标蛋白自主进入真核细胞的重组蛋白、重组表达载体和重组菌及应用<120> A recombinant protein, recombinant expression vector and recombinant bacteria that can carry target proteins into eukaryotic cells autonomously and their applications
<160> 8<160> 8
<170> SIPOSequenceListing 1.0<170> SIPOSequenceListing 1.0
<210> 1<210> 1
<211> 7<211> 7
<212> PRT<212> PRT
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 1<400> 1
Pro Lys Lys Lys Arg Lys ValPro Lys Lys Lys Arg Lys Val
1 51 5
<210> 2<210> 2
<211> 17<211> 17
<212> PRT<212> PRT
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 2<400> 2
Gly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp LysGly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys
1 5 10 151 5 10 15
LysLys
<210> 3<210> 3
<211> 51<211> 51
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 3<400> 3
cgggatccat gccaaaaaag aagagaaagg tcagtcctga ccacaccaac g 51cgggatccat gccaaaaaag aagagaaagg tcagtcctga ccacaccaac g 51
<210> 4<210> 4
<211> 83<211> 83
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 4<400> 4
cggaattctt atcatttttt ccatttcatg cggcggttct gaaaccaaat tttaatctgg 60cggaattctt atcatttttt ccatttcatg cggcggttct gaaaccaaat tttaatctgg 60
cggcccatgc cattggcgat tcc 83cggcccatgc cattggcgat tcc 83
<210> 5<210> 5
<211> 49<211> 49
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 5<400> 5
cgggatccat gccaaaaaag aagagaaagg tcgtgagcaa gggcgagga 49cgggatccat gccaaaaaag aagagaaagg tcgtgagcaa gggcgagga 49
<210> 6<210> 6
<211> 82<211> 82
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 6<400> 6
cggaattctt atcatttttt ccatttcatg cggcggttct gaaaccaaat tttaatctgg 60cggaattctt atcatttttt ccatttcatg cggcggttct gaaaccaaat tttaatctgg 60
cggcccttgt acagctcgtc ca 82cggcccttgt acagctcgtc ca 82
<210> 7<210> 7
<211> 3<211> 3
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 7<400> 7
<210> 8<210> 8
<211> 25<211> 25
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 8<400> 8
cggaattcct acatgccatt ggcga 25cggaattcct acatgccatt ggcga 25
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210384441.0A CN114716569B (en) | 2022-04-13 | 2022-04-13 | Recombinant protein, recombinant expression vector, recombinant bacteria and application of recombinant protein carrying target protein to autonomously enter eukaryotic cells |
PCT/CN2022/088658 WO2023197365A1 (en) | 2022-04-13 | 2022-04-24 | Recombinant protein carrying target protein and autonomously entering eukaryotic cell, recombinant expression vector, recombinant bacterium, and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210384441.0A CN114716569B (en) | 2022-04-13 | 2022-04-13 | Recombinant protein, recombinant expression vector, recombinant bacteria and application of recombinant protein carrying target protein to autonomously enter eukaryotic cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114716569A CN114716569A (en) | 2022-07-08 |
CN114716569B true CN114716569B (en) | 2023-11-10 |
Family
ID=82244685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210384441.0A Active CN114716569B (en) | 2022-04-13 | 2022-04-13 | Recombinant protein, recombinant expression vector, recombinant bacteria and application of recombinant protein carrying target protein to autonomously enter eukaryotic cells |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114716569B (en) |
WO (1) | WO2023197365A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116120453B (en) * | 2023-01-03 | 2023-09-26 | 华南理工大学 | A protein polymer-based engineering method for mesenchymal stem cells and its application |
CN119751643A (en) * | 2025-03-07 | 2025-04-04 | 中国农业大学 | Salivary gland apolipoprotein of Ornithodoros lahoreensis, gene, vector, recombinant bacteria and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018068135A1 (en) * | 2016-10-12 | 2018-04-19 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
WO2020120788A1 (en) * | 2018-12-14 | 2020-06-18 | Asterion Therapeutics Bvba | Repair of uv-induced dna lesions |
WO2020240248A1 (en) * | 2019-05-25 | 2020-12-03 | Helalat Seyed Hossein | Ultraviolet damage endonucleases |
CN112143752A (en) * | 2020-10-10 | 2020-12-29 | 华中农业大学 | Expression vector and reagent of fungus nucleus fluorescent marker, preparation method and application |
CN113406331A (en) * | 2020-03-16 | 2021-09-17 | 上海交通大学 | Fungal immunomodulatory protein cell positioning method based on green fluorescent protein |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6933145B1 (en) * | 1998-05-29 | 2005-08-23 | University Of Florida Research Foundation, Inc. | Materials and methods for delivery and expression of heterologous DNA in vertebrate cells |
GB0103110D0 (en) * | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
US20090130034A1 (en) * | 2005-09-27 | 2009-05-21 | Emory University | Re-engineered uv damage endonuclease, compositions and methods |
US20090054828A1 (en) * | 2007-08-22 | 2009-02-26 | Cardiac Pacemakers, Inc. | Systems for transient conduction control |
AU2018369783A1 (en) * | 2017-11-14 | 2020-05-21 | Oregon Health & Science University | Nuclear-targeted DNA repair enzymes and methods of use |
EP3717642A2 (en) * | 2017-11-30 | 2020-10-07 | Amicus Therapeutics, Inc. | Cdkl5 expression variants and cdkl5 fusion proteins |
-
2022
- 2022-04-13 CN CN202210384441.0A patent/CN114716569B/en active Active
- 2022-04-24 WO PCT/CN2022/088658 patent/WO2023197365A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018068135A1 (en) * | 2016-10-12 | 2018-04-19 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
WO2020120788A1 (en) * | 2018-12-14 | 2020-06-18 | Asterion Therapeutics Bvba | Repair of uv-induced dna lesions |
WO2020240248A1 (en) * | 2019-05-25 | 2020-12-03 | Helalat Seyed Hossein | Ultraviolet damage endonucleases |
CN113406331A (en) * | 2020-03-16 | 2021-09-17 | 上海交通大学 | Fungal immunomodulatory protein cell positioning method based on green fluorescent protein |
CN112143752A (en) * | 2020-10-10 | 2020-12-29 | 华中农业大学 | Expression vector and reagent of fungus nucleus fluorescent marker, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN114716569A (en) | 2022-07-08 |
WO2023197365A1 (en) | 2023-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114716569B (en) | Recombinant protein, recombinant expression vector, recombinant bacteria and application of recombinant protein carrying target protein to autonomously enter eukaryotic cells | |
CN115991764B (en) | Hydroxyproline modified recombinant III type humanized collagen and preparation method and application thereof | |
CN109575126B (en) | Polypeptides, method for the production and use thereof | |
CN102863539B (en) | Fusion tandem antibacterial peptide and preparation method thereof | |
AU2020104152A4 (en) | USE OF Dvl3-DEP PEPTIDE IN PREPARATION OF MEDICAMENT FOR REPAIRING SERTOLI CELL INJURY IN TESTES | |
CN118388635B (en) | Preparation method of recombinant humanized collagen for improving skin repair function | |
CN110606869A (en) | A skin healing-promoting peptide OA-GP11 and its preparation method and application | |
CN111748015B (en) | Active polypeptide OS-LL11 and application thereof | |
CN101678074B (en) | New application of extracellular superoxide dismutase and its preparation method | |
CN113980918B (en) | Antarctic ice algae MAAs synthetase, and coding gene and application thereof | |
CN107236722B (en) | A kind of application of Antarctic ice microalgae 6-4 light repair enzyme, its encoding gene and expression vector and the enzyme | |
CN112876569B (en) | rhTSG6-FN III1-C fusion protein, application thereof in skin care composition and preparation method thereof | |
CN108948151B (en) | Peptide and its preparation method and application | |
CN114763370B (en) | Antioxidant decapeptide and preparation method and application thereof | |
CN115386009B (en) | Construction method and application of annexin V and angiogenesis inhibitor fusion protein | |
CN105209480A (en) | Protransduzin b, a gene transfer enhancer | |
CN107828749A (en) | A kind of low temperature resistant superoxide dismutase MnSOD in deep-sea sea cucumber source and preparation method thereof | |
US6723548B2 (en) | DNA repair polypeptides and methods of use | |
CN102940890B (en) | Gene application in inhibition and apoptosis of glioma cell | |
CN1295332C (en) | Recombination human alkaline fiber forming cell growth factor gene and its nonfusion expression product, production method and application | |
CN111434693B (en) | Antioxidant fusion protein and application thereof | |
CN106943588A (en) | Applications of the heat shock protein gp96 in treatment psoriasis | |
CN103880964B (en) | A kind of recombination fusion protein VIP-TAT and application thereof | |
LU509212B1 (en) | Use of lamg34 peptide in preparing drug for repairing testicular damage and product development | |
CN101144088A (en) | Dunaliella salina CPD photolyase, photolyase liposome prepared therefrom and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |